Caicong You
Fuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Cost-effectiveness of perioperative durvalumab plus FLOT for resectable gastric and gastroesophageal junction adenocarcinoma in the United States.
Journal: Frontiers in immunology
Published: September 24, 2025
Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China.
Journal: World journal of urology
Published: May 23, 2025
Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.
Journal: Diabetes, obesity & metabolism
Published: April 03, 2025
Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Journal: Therapeutic advances in medical oncology
Published: January 02, 2025
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States.
Journal: Therapeutic advances in medical oncology
Published: December 27, 2024
Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer.
Journal: Scientific reports
Published: August 27, 2024
Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China.
Journal: Frontiers in oncology
Published: August 22, 2024
Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.
Journal: Therapeutic advances in medical oncology
Published: July 09, 2024
First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis.
Journal: Therapeutic advances in gastroenterology
Published: June 17, 2024
First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: March 19, 2024
Showing 1-10 of 10
Last Updated: 09/26/2026